Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

When Alzheimer's was first identified: Auguste Deter and the century after

Last reviewed November 15, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

For most of history, losing your memory in old age was considered part of getting old. Alzheimer's disease became a named illness only in the 1900s, and only because one doctor followed a single patient from her first symptoms to her autopsy.

Here are the moments that turned senility into a disease with known proteins, known genes, and the first treatments that slow it.

Related pages: Memory loss and dementia (Alzheimer's)

The bottom line

What we know
  • Alois Alzheimer described the first case publicly on 3 November 1906 and published it in 1907.
  • Emil Kraepelin gave the disease Alzheimer's name in 1910.
  • The two proteins were identified much later: amyloid in 1984, tau in tangles in 1986.
What is still open
  • Why Kraepelin named it after Alzheimer when others were describing similar cases at the same time. Historians still debate his motives.

The timeline

  1. 1. Before 1900 (Doctors through the 1800s)
  2. 2. 1901: Auguste Deter (Alois Alzheimer and his patient Auguste Deter)
  3. 3. 1906: The lecture (Alois Alzheimer)
  4. 4. 1910: The name (Emil Kraepelin, Alzheimer's former boss)
  5. 5. 1984 to 1986 (George Glenner and Caine Wong, 1984; several teams on tau, 1986)
  6. 6. 1997 to 1998 (Manuel Graeber and colleagues)
  7. 7. 1993 to today (Many research groups)
Moment 1 of 7

Losing your mind in old age was thought to be normal

Doctors through the 1800s

What happened

Older people with failing memory were described as senile or suffering from 'senility', understood as the brain simply wearing out, often blamed on hardened arteries.

What was found

  • There was no distinction between different causes of dementia.
  • A few doctors in the 1800s described plaques in older brains, but nobody tied them to a specific illness.

Why it matters

Until a disease has a name and a definition, it can't be studied, counted or treated.

What historians and scientists debate

  • Some historians argue the shift was as much about which patients doctors were paid to study as about new science.

Read more

Next: 1901: Auguste Deter

Moment 2 of 7

A 51-year-old woman arrives at the Frankfurt asylum

Alois Alzheimer and his patient Auguste DeterFrankfurt, Germany

What happened

In November 1901, Alzheimer examined a 51-year-old woman whose husband had brought her in. She was confused, jealous of her husband without reason, couldn't remember what she had just been told, and couldn't find her way around her own home.

What was found

  • Alzheimer wrote out their conversations in detail. Asked to write her name, she couldn't finish it.
  • Her case notes record her saying she had, in effect, lost herself.
  • She declined over four and a half years and died on 8 April 1906. Alzheimer arranged to receive her records and her brain.

Why it matters

Her age was the point. Memory loss this severe in someone in her fifties didn't fit the 'normal aging' explanation, which is what made the case worth pursuing.

What historians and scientists debate

  • Her care was tangled up in money. Her husband asked for her to be moved somewhere cheaper, and Alzheimer intervened to keep her where she was.

Read more

Next: 1906: The lecture

Moment 3 of 7

Alzheimer describes the plaques and tangles, and nobody cares

Alois AlzheimerTubingen, Germany, 37th meeting of the Southwest German Psychiatrists

What happened

Using new staining methods, Alzheimer examined Deter's brain under the microscope and presented what he found on 3 November 1906, in a talk titled 'On a peculiar disease of the cerebral cortex'.

What was found

  • He described two things together in one brain: deposits between the nerve cells (now called amyloid plaques) and tangled fibers inside them (now called neurofibrillary tangles).
  • The audience showed little interest. There were no questions, and the next speaker moved on to another topic.
  • He published a short write-up in 1907 and a fuller paper, with a second patient, in 1911.

Why it matters

This is the founding description of the disease: the symptoms in life and the two changes in the brain, linked in one person for the first time.

What historians and scientists debate

  • Alzheimer wasn't alone. Oskar Fischer in Prague described plaques in 12 cases of senile dementia in 1907, and others followed. Some historians argue the disease might fairly have been named for both men.

Read more

Next: 1910: The name

Moment 4 of 7

Kraepelin names it Alzheimer's disease

Emil Kraepelin, Alzheimer's former bossMunich, Germany

What happened

Kraepelin, the most influential psychiatrist of the era, was revising the 8th edition of his psychiatry textbook.

What was found

  • In the chapter on presenile and senile dementia, he set out this illness separately and called it Alzheimer's disease.
  • He drew the line by age, treating it as a disease of middle age rather than old age. That distinction was dropped decades later when it became clear the same changes cause most dementia in old age too.

Why it matters

The name stuck, and with it the idea that this is a disease rather than aging.

What historians and scientists debate

  • Kraepelin's reasons are debated. Suggestions range from scientific conviction to institutional rivalry with researchers in Prague.

Read more

Next: 1984 to 1986

Moment 5 of 7

The two proteins finally get identified

George Glenner and Caine Wong, 1984; several teams on tau, 1986United States and elsewhere

What happened

For 80 years, nobody knew what plaques and tangles were made of. New protein chemistry changed that.

What was found

  • In 1984 Glenner and Wong purified the protein from blood-vessel deposits in an adult with Down syndrome and sequenced it. It matched the protein in Alzheimer's plaques. They named it beta-amyloid.
  • Because people with Down syndrome have an extra copy of chromosome 21, this pointed researchers to that chromosome, where the amyloid precursor gene was found in 1987.
  • In 1986 several teams showed the tangles were made of an altered form of tau.

Why it matters

Naming the proteins is what made modern Alzheimer's research possible: genes to hunt, scans to build, and drug targets to aim at.

What historians and scientists debate

  • Identifying what plaques are made of didn't settle whether they cause the disease. Forty years later, that is still argued over.

Read more

Next: 1997 to 1998

Moment 6 of 7

Auguste Deter's own slides are found in a Munich basement

Manuel Graeber and colleaguesUniversity of Munich

What happened

Deter's case file resurfaced in the 1990s, and some researchers argued her dementia had really been caused by hardened arteries rather than the disease named after her. The slides Alzheimer actually looked at had been missing for decades. A search of the old laboratory collection turned them up.

What was found

  • Her brain sections showed large numbers of both amyloid plaques and neurofibrillary tangles.
  • By modern standards, she was a typical case of the disease named for her.
  • The slides of Alzheimer's second published patient, Johann F., were also found. His brain had plaques but no tangles, an early glimpse of how varied the disease is.

Why it matters

A century-old diagnosis was checked against modern criteria and held up.

What historians and scientists debate

  • Genetic testing on her tissue has been attempted, with results that are still debated.

Read more

Next: 1993 to today

Moment 7 of 7

Genes, scans, blood tests, and the first drugs that slow it

Many research groups

What happened

The pace picked up through the 1990s and 2000s.

What was found

  • In 1993, APOE4 was identified as the main gene raising risk for the common late-onset form.
  • Brain scans that show amyloid, then tau, arrived in the 2000s and 2010s, letting doctors see the disease in living people for the first time.
  • Blood tests for Alzheimer's proteins arrived in the 2020s, making diagnosis far easier than a spinal tap or a scan.
  • Lecanemab and donanemab, antibodies that clear amyloid, were approved in the US in 2023 and 2024. They slow early Alzheimer's modestly and carry a risk of brain swelling and small bleeds.

Why it matters

In roughly 120 years, Alzheimer's went from one woman's unexplained illness to a disease that can be detected decades early with a blood test and treated, a little.

What historians and scientists debate

  • There is still no cure, and no treatment restores lost memory.
  • The new drugs only suit people diagnosed early who meet strict criteria.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.